<DOC>
	<DOCNO>NCT00288626</DOCNO>
	<brief_summary>The purpose study determine effectiveness new treatment multiple sclerosis ( MS ) , serious disease immune system attack brain spinal cord . MS progressive severe lead significant disability . The study treatment involve use high-dose chemotherapeutic drug suppress immune system . The participant 's ( autologous ) blood-forming ( hematopoietic , CD34+ ) stem cell collect chemotherapy give , transplant back body follow treatment . Transplantation autologous hematopoietic stem cell require prevent prolong period low blood cell count high-dose chemotherapy .</brief_summary>
	<brief_title>High-Dose Immunosuppression Autologous Transplantation Multiple Sclerosis ( HALT MS ) Study</brief_title>
	<detailed_description>MS chronic autoimmune disease central nervous system myelin , protective coat surround nerve cell , damage destroy autoimmune T cell macrophage , lead eventual loss neurologic function . In pilot study Europe use high-dose chemotherapy , observe 18 19 MS patient stabilize improve clinically , one patient show new lesion magnetic resonance imaging ( MRI ) brain 4.5 year treatment . Improvement see quality-of-life assessment . In ITN033AI , high-dose chemotherapy autologous CD34-selected hematopoietic cell transplantation give confirm result pilot study offer therapy patient early MS poor prognosis . Research study perform addition clinical assessment well understand effect treatment activity MS. High-dose chemotherapy use deplete autoreactive immune cell . These regimen also deplete bone marrow , source blood-forming CD34+ stem cell cause low blood count . Therefore , participant 's autologous CD34+ hematopoietic stem cell collect high dose immunosuppressive therapy give return transplant post-chemotherapy . Patients follow closely autologous transplantation since risk infection treatment . At begin study , participant undergo number screen baseline procedure , include physical exam , blood collection , MS-confirming neurology exam questionnaire , MRI procedure . Participants give prednisone granulocyte-colony stimulating factor ( G-CSF ) mobilize CD34+ hematopoietic stem cell bone marrow peripheral blood . When peripheral blood CD34+ cell count reach 20,000 cells/ml great , cell collect leukapheresis . In process , catheter place large blood vessel , peripheral blood withdrawn , high speed sedimentation ( leukapheresis ) device use separate retain cell require autologous transplantation . Other blood cell return participant 's body . In laboratory , CD34+ hematopoietic stem cell graft select prepared leukapheresis collection , store need transplant . Seven day follow collection autologous graft , participant hospitalize receive high-dose chemotherapy consist carmustine , etoposide , cytarabine , melphalan ( BEAM ) thymoglobulin . This follow transplantation autologous hematopoietic cell graft . Participants remain hospital observation recovery peripheral blood cell count , describe protocol . Participants receive G-CSF blood transfusion , need , monitored infection . Following discharge hospital , eight study visit occur sixty month ( five year ) . During visit , participant undergo blood urine collection , MRI study , leukapheresis , MS neurology exam complete questionnaire .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis relapsingremitting progressiverelapsing multiple sclerosis le 15 year use McDonald Criteria . More information criterion find protocol Score 3.0 5.5 Expanded Disability Status Scale ( EDSS ) T2 abnormalities brain MRI consistent MS Two relapse 18 month time interferon ( IFN ) , glatiramer acetate ( GA ) , natalizumab cytotoxic therapy EDSS increase 1.0 great participant EDSS screen 3.0 3.5 ( 0.5 great participant EDSS screen 4.0 5.5 ) sustain least 4 week least one relapse OR one relapse IFN , GA , natalizumab cytotoxic therapy EDSS increase 1.5 great ( 1.0 subject EDSS screen 5.5 ) sustain least 4 week , together MRI change consistent poor prognosis . More information criterion find protocol . On IFN GA least 6 month relapse occur count satisfy previous inclusion criterion OR receive adequate dos natalizumab cytotoxic therapy treatment schedule relapse occur count satisfy previous inclusion criterion Approval MS Review Panel participate study . More information criterion find protocol In good clinical condition adequate organ function without coexist medical problem would increase risk participant Willing use acceptable method contraception Willing able comply study requirement Willing accept comprehend irreversible sterility side effect therapy . Primary progressive MS Secondary progressive MS without relapse ( i.e. , progression without exacerbation relapse ) 12 month Neuromyelitis optica , disease similar MS Initiation new immunosuppressant treatment participant become eligible protocol continuance immunosuppressant drug participant screen protocol . Treatment IFN , GA , corticosteroid permit participant becomes eligible protocol . Lapse great 6 month time participant eligible protocol initiation protocol treatment except judge acceptable MS Review Panel Prior treatment investigational immunosuppressive agent within 3 month study eligibility Positive baseline plasma CSF test JC virus brain MRI change consistent diagnosis progressive multifocal encephalopathy ( PML ) History cytopenia consistent diagnosis myelodysplastic syndrome ( MDS ) Active hepatitis B C infection , cirrhosis , HIV infection Uncontrolled diabetes mellitus Uncontrolled viral , fungal , bacterial infection . Patients asymptomatic bacteriuria exclude Any illness would jeopardize ability tolerate aggressive chemotherapy Prior history malignancy , except localize basal cell squamous skin cancer . Other malignancy subject judge cured administer therapy consider individual basis . Hypersensitivity mouse , rabbit , Escherichia coliderived protein iron compounds/medications Metallic object implant body would affect MRI exam Psychiatric illness , mental deficiency , cognitive dysfunction Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hematopoietic stem cell transplantation</keyword>
	<keyword>HCT- autologous hematopoietic cell transplant</keyword>
	<keyword>HDIT-high-dose immunosuppressive therapy</keyword>
	<keyword>BEAM -Carmustine ( BCNU ) , Etoposide ( VP-16 ) , Cytarabine ( ara-C ) , Melphalan</keyword>
</DOC>